PRESS-RELEASE filed Jun 8, 2026 at 07:30 ET
Standard BioTools (LAB) announced a definitive all-stock merger with Treeline Biosciences, a clinical-stage oncology biotech. LAB shareholders will own ~16% of the combined company (Treeline Biosciences, ticker TRLN), valued at net cash delivered at closing plus $10M (~$460M). The combined entity will have >$900M cash, funding operations into 2029, and Treeline's pipeline includes three Phase 1 programs with data readouts starting 2027. LAB's legacy Mass Cytometry and Microfluidics businesses will be divested. This is a transformative reverse-merger that effectively converts LAB into a development-stage biotech, with LAB shareholders receiving a minority stake and a CVR tied to legacy asset proceeds.